Plus therapeutics, inc. (CYTX)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10
Product revenues

-

-

-

-

-

-

-

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Third party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

7,983

6,845

6,802

0

0

0

Product revenues

-

-

-

-

-

-

-

-

-

-

-

3,757

3,914

4,656

4,746

4,781

5,269

4,838

5,751

5,503

4,824

4,953

5,190

6,288

6,761

7,122

8,383

8,081

8,620

8,709

0

0

0

-

-

-

-

0

0

Cost of product revenues

-

-

-

-

-

-

-

-

0

-

1,630

2,010

2,112

2,170

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of intangible assets

-

-

-

-

-

-

-

-

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gross profit

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of intangible assets

-

-

-

-

-

-

-

-

-

-

-

-

752

545

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of product revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,186

3,812

3,647

3,117

2,940

2,650

3,244

3,086

3,421

3,707

3,479

3,903

4,000

3,532

3,771

3,848

3,837

3,813

3,754

0

0

0

Gross profit (loss)

-

-

-

-

-

-

-

-

-

-

638

771

1,050

1,941

2,186

2,337

2,114

1,652

1,939

1,856

1,707

2,013

2,540

3,044

3,675

3,701

4,676

4,602

4,717

4,709

3,286

3,867

4,254

4,146

3,613

3,629

0

0

0

Development revenues:
Development, related party

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

638

1,107

1,107

3,520

2,882

3,174

3,174

761

1,992

1,231

1,231

0

0

0

Development revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

Government contracts and other

6,379

6,998

6,523

2,206

2,803

2,983

3,137

3,989

3,621

3,722

4,416

4,989

6,157

6,724

6,982

6,814

6,962

6,821

6,303

5,177

3,686

2,645

2,098

2,608

3,111

3,257

2,863

1,770

927

381

0

0

0

-

-

-

-

-

-

Total development revenues

-

-

6,523

2,206

-

2,983

3,137

3,989

3,621

3,722

4,416

4,989

6,157

6,724

0

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research grant and other

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

0

Total development revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

5,074

7,678

6,585

8,155

5,792

3,196

3,199

781

2,013

1,316

1,318

0

0

0

Operating expenses:
Research and development

4,880

5,365

4,167

4,472

4,450

5,523

7,385

9,163

10,888

11,678

12,148

13,104

15,359

16,197

17,971

18,363

19,164

19,000

17,362

16,150

14,776

15,105

17,178

18,161

17,637

17,065

16,006

15,438

14,512

13,628

11,571

10,846

10,693

10,904

11,428

10,899

0

0

0

Sales and marketing

464

468

-33

-9

79

643

1,532

2,254

3,332

3,593

3,911

3,889

3,515

3,611

3,345

3,093

2,858

2,662

3,132

4,037

5,317

6,406

7,906

8,221

8,697

9,026

8,534

9,198

9,369

9,488

10,407

11,575

12,710

13,560

13,492

12,299

0

0

0

General and administrative

4,967

4,822

4,019

4,280

4,698

5,579

6,456

6,904

7,730

7,594

7,950

8,176

8,385

8,563

8,728

9,087

9,552

9,765

10,494

12,303

14,112

15,953

16,928

17,081

16,525

16,031

16,407

15,852

15,594

15,672

14,987

14,748

15,107

14,727

14,289

13,803

0

0

0

Change in fair value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-2,780

-7,566

0

-

0

0

-

-

-

Change in fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Change in fair value of option liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,250

2,400

2,100

-860

-340

-1,910

-1,040

-180

-740

660

30

0

0

0

Total operating expenses

10,311

10,655

8,153

8,743

9,227

11,745

15,373

18,321

21,950

24,551

25,695

26,855

28,945

28,371

27,364

20,553

8,462

23,759

25,765

34,443

49,280

37,095

41,878

43,463

40,275

39,454

36,676

37,380

39,662

38,919

38,113

36,188

31,569

35,571

37,958

35,195

0

0

0

Operating loss

-3,932

-3,657

-1,782

-6,689

-6,576

-8,762

-12,055

-14,171

-17,906

-20,683

-20,641

-21,095

-21,738

-19,706

-18,196

-11,402

614

-15,286

-17,523

-27,410

-43,887

-32,437

-37,240

-37,811

-33,489

-30,679

-24,322

-26,193

-26,790

-28,418

-31,631

-29,122

-26,534

-29,412

-33,029

-30,248

0

0

0

Other income (expense):
Income (loss) on asset disposal

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

Loss on debt extinguishment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

0

0

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

Interest income

84

55

33

38

36

43

40

34

36

33

34

33

28

19

10

9

10

9

9

7

5

6

6

6

6

4

3

2

2

4

6

9

9

9

9

8

0

0

0

Interest expense

1,689

1,855

2,020

2,167

2,014

1,922

1,826

1,787

1,881

2,049

2,248

2,419

2,526

2,592

2,649

2,673

2,964

3,379

3,762

4,353

4,502

4,371

4,227

4,061

3,628

3,396

3,259

3,022

3,230

3,386

3,443

3,075

2,911

2,784

2,682

2,447

0

0

0

Other income (expense), net

-

-

-

-

-

-

-

-

200

13

-463

-414

-15

233

940

1,085

475

172

-253

-674

-584

-608

-239

-113

-179

-438

-616

-537

-440

-314

-109

-67

-55

-55

-64

-138

0

0

0

Change in fair value of warrants

-4,864

-3,407

-488

-2,725

-2,443

-2,233

0

0

0

-

-

-

-

-

-

-

-

-7,668

-5,223

1,953

15,075

-369

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance cost of warrants

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on Puregraft divestiture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Gain on previously held equity interest in joint venture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

0

0

-

-

-

-

-

-

-

Equity loss from investment in joint venture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-48

-84

-126

-163

-165

-185

-194

-213

-209

-196

-179

0

0

0

Total other income (expense)

2,026

374

-3,211

-226

-357

-116

-321

-1,616

-1,645

-2,003

-2,677

-2,800

-2,513

-2,340

-1,695

-1,578

-2,739

-3,458

-4,213

-5,238

-5,039

-4,931

-4,414

284

4,579

4,502

4,363

244

-3,831

-3,861

-3,731

-3,327

-3,170

-3,039

-2,933

-2,756

0

0

0

Loss from continuing operations

-1,906

-3,283

-5,601

-8,412

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from discontinued operations

-

-7,604

-8,502

-9,874

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-8,824

-10,887

-14,007

-16,863

-11,375

-12,634

-14,684

-17,161

-19,551

-22,686

-23,318

-23,895

-24,251

-22,046

-19,891

-12,980

-2,125

-18,744

-21,736

-32,648

-48,926

-37,368

-41,654

-37,527

-28,910

-26,177

-19,959

-25,949

-30,621

-32,279

-35,362

-32,449

-29,704

-32,451

-35,962

-33,004

0

0

0

Income (Loss) from continuing operations

0

-

0

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Beneficial conversion feature for convertible preferred stock

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

661

1,830

508

1,830

1,169

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss allocable to common stockholders - continuing operations

-

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss allocable to common stockholders - discontinued operations

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss allocable to common stockholders

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-19,405

-23,566

-34,478

-50,756

-38,537

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted net loss per share attributable to common stockholders - continuing operations

-0.28

9.36

-0.03

-5.12

-6.98

-

-22.27

-18.53

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted net loss per share attributable to common stockholders - discontinued operations

-

8.48

3.52

-15.55

-1.94

-

-5.36

-11.14

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss per share, basis and diluted

-0.28

21.35

-0.03

-20.67

-8.92

-28.95

-27.63

-29.67

-0.73

-4.57

-1.39

-1.94

-0.33

-0.18

-0.26

-0.43

-0.41

-

-

-

-3.19

-

-

-

-0.14

-0.15

-0.08

-0.05

-0.11

-0.07

-0.19

-0.13

-0.16

-

-0.15

-0.10

-

-

-

Basic and diluted weighted average shares used in calculating net loss per share attributable to common stockholders

3,880

3,913

826

442

353

-5,620

174

123

6,017

-16,354

3,449

3,125

22,736

20,804

20,493

14,778

13,086

-

-

-

7,080

-

-

-

74,102

69,685

67,248

67,200

66,990

59,844

58,713

58,676

57,484

-

53,900

52,411

-

-

-

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.15

0.48

-

-

-0.12

-0.15

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0.15

0.45

-

-

-0.12

-0.15

-

-

-

-

-

-

-

-

-

-

-

-

-0.23

-0.23

-0.12

Basic

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,253

9,266

-

-

80,430

76,682

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,531

9,824

-

-

80,430

76,682

-

-

-

-

-

-

-

-

-

-

-

-

51,994

45,905

45,295

Comprehensive loss:
Net loss

-8,824

-10,887

-14,007

-16,863

-11,375

-12,634

-14,684

-17,161

-19,551

-22,686

-23,318

-23,895

-24,251

-22,046

-19,891

-12,980

-2,125

-18,744

-21,736

-32,648

-48,926

-37,368

-41,654

-37,527

-28,910

-26,177

-19,959

-25,949

-30,621

-32,279

-35,362

-32,449

-29,704

-32,451

-35,962

-33,004

0

0

0

Other comprehensive loss – foreign currency translation adjustments

-

-

-

-

-28

-169

-17

54

-92

129

524

566

451

262

-386

-334

11

296

604

552

530

444

599

433

316

256

-142

-34

-110

0

0

0

0

-

-

-

-

-

-

Comprehensive loss

-8,684

-10,887

-14,111

-17,022

-11,403

-12,803

-14,701

-17,107

-19,643

-22,557

-22,794

-23,329

-23,800

-21,784

-20,277

-13,314

-2,114

-18,448

-21,132

-32,096

-48,396

-36,924

-41,055

-37,094

-28,594

-25,921

-20,101

-25,983

-30,731

-32,279

0

0

0

-

-

-

-

-

-